Keynote 057: Phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG) Meeting Abstract
| Authors: | Balar, A. V.; Kulkarni, G. S.; Uchio, E. M.; Boormans, J.; Mourey, L.; Krieger, L. E. M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; Seo, H. K.; Nishiyama, H.; Konety, B. R.; Nam, K.; Kapadia, E.; Frenkl, T. L.; De Wit, R. |
| Abstract Title: | Keynote 057: Phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG) |
| Meeting Title: | 2019 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 7 Suppl. |
| Meeting Dates: | 2019 Feb 14-16 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-03-01 |
| Language: | English |
| ACCESSION: | WOS:000489108800369 |
| DOI: | 10.1200/JCO.2019.37.7_suppl.350 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 350 -- Source: Wos |
